NCT01388764View on ClinicalTrials.gov

Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
DystrophinopathyDuchenne Muscular DystrophyBecker's Muscular Dystrophy
Interventions
DRUG

L-arginine

Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01388764 - Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids | Biotech Hunter | Biotech Hunter